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Cardiac remodeling progresses to heart failure, which represents a major cause of
morbidity and mortality. Cardiomyokines, cardiac secreted proteins, may play roles
in cardiac remodeling. Fibroblast growth factors (FGFs) are secreted proteins with
diverse functions, mainly in development and metabolism. However, some FGFs play
pathophysiological roles in cardiac remodeling as cardiomyokines. FGF2 promotes cardiac
hypertrophy and fibrosis by activating MAPK signaling through the activation of FGF
receptor (FGFR) 1c. In contrast, FGF16 may prevent these by competing with FGF2 for the
binding site of FGFR1c. FGF21 prevents cardiac hypertrophy by activating MAPK signaling
through the activation of FGFR1c with β-Klotho as a co-receptor. In contrast, FGF23
induces cardiac hypertrophy by activating calcineurin/NFAT signaling without αKlotho.
These FGFs play crucial roles in cardiac remodeling via distinct action mechanisms. These
findings provide new insights into the pathophysiological roles of FGFs in the heart and
may provide potential therapeutic strategies for heart failure.
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INTRODUCTION
Heart failure represents a major cause of morbidity and mortality
and remains a critical health problem. Cardiac hypertrophy and
fibrosis subsequently progress to heart failure. Proteins secreted
from the heart with functions crucial for its function have been
referred to as cardiomyokines. Cardiomyokines may play roles
in cardiac remodeling and heart failure. Identifying the under-
lying molecular targets and novel protective agents of cardiac
remodeling is important for improving preventive and therapeu-
tic strategies. Cardiomyokines may be therapeutic targets and/or
agents (Fredj et al., 2005; Doroudgar and Glembotski, 2011).
Fibroblast growth factors (FGFs) are signaling proteins of
∼150–300 amino acids with diverse functions, mainly in devel-
opment and metabolism. The mammalian FGF family comprises
twenty-two members. FGFs can be classified to as intracellular
FGFs (iFGFs), canonical FGFs, and hormone-like FGFs (hFGFs)
by their action mechanisms. Intracellular, canonical, and hFGFs
are also referred to as intracrine, paracirne, and endocrine FGFs,
respectively. Paracrine and endocrine FGFs are secreted signals,
mainly in paracrine and endocrine manners, respectively (Itoh
and Ornitz, 2011).
Among these FGFs, FGF2, FGF16, FGF21, and FGF23 have
been shown to play pathophysiological roles in the heart. These
FGFs play distinct roles in cardiac remodeling via unique action
mechanisms. Although their action mechanisms remain unclear,
these findings provide new insights into the pathophysiological
roles of FGFs in the heart and may provide potential therapeutic
strategies for heart failure. In this article, we provide a succinct
review of the pathophysiological roles of these FGFs in the heart
revealed by recent studies using gene-targeted mouse models.
THE FGF AND FGFR FAMILIES
The human/mouse Fgf gene family comprises twenty-two mem-
bers, Fgf1-Fgf23. Fgf15, and Fgf19 are orthologous genes in
mice and humans, respectively. These genes are also referred to
as Fgf15/19. FGFs are proteins of ∼150–300 amino acids with
a conserved core of ∼120 amino acids with ∼30–60% iden-
tity. Phylogenetic analysis of the Fgf gene family has identified
seven subfamilies; Fgf/1/2, Fgf4/5/6, Fgf3/7/10/22, Fgf8/17/18,
Fgf9/16/20, Fgf11/12/13/14, and Fgf15/19/21/23 (Figure 1) (Itoh
and Ornitz, 2011).
Paracrine FGFs, which comprise fifteen members belong-
ing to the FGF/1/2, FGF4/5/6, FGF3/7/10/22, FGF8/17/18, and
FGF9/16/20 subfamilies, mediate biological responses by bind-
ing to and activating cell surface tyrosine kinase FGF receptors
(FGFRs) with heparin/heparan sulfate as a cofactor. They func-
tion as paracrine signaling molecules, of which functions have
been mostly studied in development. Endocrine FGFs, FGF15/19,
FGF21, and FGF23, also mediate their biological responses in
an FGFR-dependent manner. However, they bind to FGFRs with
heparin/heparan sulfate with very low affinity. This reduced
heparin-binding affinity enables endocrine FGFs to function
over long distances in an endocrine manner. They require
either αKlotho or βKlotho, which is a single-pass trans-
membrane protein with a short cytoplasmic domain, as a
cofactor instead of heparin/heparan sulfate. They function
as hormone-like signaling molecules, mainly in metabolism
(Itoh, 2010; Itoh and Ornitz, 2011; Long and Kharitonenkov,
2011; Goetz and Mohammadi, 2013). Intracrine FGFs, FGF11-
FGF14, are intracellular proteins that regulate the function
of voltage-gated sodium channels in an intracrine manner
(Goldfarb, 2012).
Four Fgfr genes, Fgfr1–Fgfr4, have been identified in mam-
mals. These genes encode receptor tyrosine kinases that contain
an extracellular ligand-binding domain, transmembrane domain,
and split intracellular tyrosine kinase domain. Fgfr1–Fgfr3 encode
two major variants generated by alternative splicing. Thus, seven
FGFR proteins (FGFRs 1b, 1c, 2b, 2c, 3b, 3c, and 4) with differing
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ligand-binding specificities have been generated (Zhang et al.,
2006).
Paracrine and endocrine FGFs induce the phosphorylation of
specific cytoplasmic tyrosine residues in FGFRs. The phosphory-
lation triggers the activation of cytoplasmic signal transduction
pathways, which elicits different cell responses. The activated
FGFRs first activate their intracellular substrates, FGFR sub-
strate 2α (FRS2α) and/or phospholipase Cγ1 (PLCγ1). Activated
FRS2α initiates downstream signaling through the RAS–MAPK
or PI3K–AKT pathway. Although cell responses depend on FGFs
and their targeted cells, the RAS–MAPK pathway mainly gen-
erates a mitogenic cell response, while the PI3K–AKT pathway
mainly promotes cell survival. The activation of PLCγ1 leads to
the release of calcium ions from intracellular stores and activation
of calcium-dependent signaling. The PLCγ1 pathway is thought
to play a role in mediating cell motility (Goetz and Mohammadi,
2013).
ROLES OF FGF2 IN CARDIAC REMODELING
FGF2 is a paracrine FGF. Although most paracrine FGFs are
secreted proteins with N-terminal signal sequences, FGF2 with
FIGURE 1 | Evolutionary relationships within the human/mouse Fgf
gene family by phylogenetic analysis. Phylogenetic analysis suggests
that twenty-two Fgf genes can be arranged into seven subfamilies
containing two to four members each. Branch lengths are proportional to
the evolutionary distance between each gene (Itoh and Ornitz, 2011).
no signal sequence is not a typical secreted protein. FGF2 may
be released from damaged cells or by an exocytotic mechanism
that is independent of the endoplasmic reticulum-Golgi pathway
(Nickel, 2010). However, FGF2 as well as other paracrine FGFs
mediates biological responses as extracellular proteins by bind-
ing to and activating FGFRs with heparin/heparan sulfate as a
cofactor (Itoh and Ornitz, 2011).
Although Fgf2 is broadly expressed in mice, Fgf2 knockout
mice are viable. However, cardiac hypertrophy and fibrosis were
less developed in Fgf2 knockout mice with myocardial infarcts
(Virag et al., 2007). Isoproterenol-induced cardiac hypertrophy
was shown to be protected in Fgf2 knockout mice (House et al.,
2010). The two-kidney one-clip (2K1C) model increased blood
renin and angiotensin II levels, leading to a chronic elevation in
blood pressure and compensatory cardiac hypertrophy. However,
2K1C-induced cardiac hypertrophy and fibrosis did not develop
in Fgf2 knockout mice (Pellieux et al., 2001).
FGF2 caused hypertrophy by inducing MAPK signaling in cul-
tured cardiomyocytes (Bogoyevitch et al., 1994; Kaye et al., 1996).
The cardiac-specific Fgf2-overexpression in transgenic mice exac-
erbated hypertrophy and the effect was blunted in the presence
of a pharmacological ERK inhibitor, which also indicated the
involvement of FGF2-induced MAPK signaling (House et al.,
2010). The heart was shown to predominantly express Fgfr1c
among Fgfrs (Fon Tacer et al., 2010). FGF2 effectively activates
FGFR1c with heparin/heparin sulfate in non-cardiac cell types
(Zhang et al., 2006). Although these findings do not necessary
mean that FGFR1c is a FGF2 receptor in the heart, FGF2 might
act on cardiac cells in a paracrine manner and promotes cardiac
remodeling by activating MAPK signaling through the activation
of FGFR1c (Table 1).
ROLES OF FGF16 IN CARDIAC REMODELING
FGF16 is also a paracrine FGF. Fgf16 gene is predominantly
expressed in the heart (Fon Tacer et al., 2010). However, heart
function is essentially normal in Fgf16 knockout mice (Hotta
et al., 2008). Angiotensin II induces cardiac hypertrophy and
fibrosis. Transforming growth factor- β1 (Tgf- β1) acts down-
stream of angiotensin II and promotes cardiac hypertrophy
and fibrosis (Rosenkranz, 2004). Angiotensin II-induced cardiac
hypertrophy and fibrosis were shown to be significantly pro-
moted by enhancing Tgf- β1 expression in Fgf16 knockout mice
(Matsumoto et al., 2013). The response to cardiac remodeling was
apparently opposite to that in Fgf2 knockout mice, as described
above.
The biochemical properties of FGF16 are distinct from those
of FGF2. Fgf16 is expressed mainly in cardiomyocytes. FGF16
is efficiently secreted and acts as a paracrine signaling molecule
Table 1 | Roles of FGFs 2, 16, 21, and 23 in cardiac remodeling.
Remodeling Receptor Signaling Action manner
FGF2 Promotion FGFR1c/Heparan sulfate MAPK Agonist/Paracrine
FGF16 Prevention FGFR1c/Heparan sulfate MAPK Antagonist/Paracrine
FGF21 Prevention FGFR1c/βKlotho MAPK Agonist/Paracrine
FGF23 Promotion FGFR1c? Calcineurin/NEAT Agonist/Endocrine
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(Hotta et al., 2008). In contrast, FGF2, which is mainly expressed
in non-cardiomyocytes, is not a typical secretory protein. FGF2,
which is stored in these cells, is released in response to hemody-
namic stress (Kaye et al., 1996). FGF2 showed significant pro-
liferative activity in cultured cardiomyocytes, where as FGF16
did not. However, FGF16 antagonized the activity of FGF2 (Lu
et al., 2008). FGF16 competed with FGF2 for the binding site of
FGFR1c, which is predominantly expressed in the heart (Lu et al.,
2008). In addition, FGF2 significantly induced Tgf- β1 expres-
sion in cultured cardiomyocytes and non-cardiomyocytes, where
as FGF16 did not. However, FGF16 inhibited FGF2-induced Tgf-
β1 expression, indicating that FGF16 antagonizes FGF2-induced
Tgf-β1 expression. Cardiac Fgf16 expression was induced after
the induction of Fgf2 expression by angiotensin II. In cultured
cardiomyocytes, Fgf16 expression was promoted by FGF2. These
findings indicate a possible mechanism in which FGF16 may pre-
vent cardiac hypertrophy and fibrosis by competing with FGF2
for the binding site of FGFR1c (Table 1) (Matsumoto et al.,
2013).
ROLES OF FGF21 IN CARDIAC REMODELING
FGF21 is an endocrine FGF. FGF21 also mediates its biological
responses in an FGFR-dependent manner. However, FGF21 binds
to FGFRs with heparin/heparan sulfate with very low affinity.
FGF21 efficiently binds to and activates FGFR1c, FGFR2c, and
FGFR3c with βKlotho, which is crucial for FGF21 signaling as a
cofactor (Kharitonenkov et al., 2008; Suzuki et al., 2008). Fgf21
is expressed mainly in the liver. Fgf21 knockout and transgenic
mice suggest the diverse metabolic actions of FGF21 in glu-
cose and lipid metabolism (Itoh, 2010; Long and Kharitonenkov,
2011).
Fgf21 knockout mice also exhibited an increased relative heart
weight and develop enhanced signs of dilatation. In response to
isoproterenol infusion, cardiac hypertrophy was more enhanced
in Fgf21 knockout mice. FGF21 reversed cardiac hypertrophy
in Fgf21 knockout mice and cultured cardiomyocytes. FGF21 is
also produced by cardiomyocytes. Although cardiac FGF21 secre-
tion is lower than hepatic FGF21 secretion, FGF21 is markedly
secreted by cardiac cells in response to cardiac stress, and car-
diac FGF21 secretion is able to inhibit isoproterenol-induced
cardiac hypertrophic damage. Thus, the heart appears to be
a target of locally generated FGF21, even though FGF21 is
an endocrine FGF. Both Fgfr1c and β-Klotho are predomi-
nantly expressed in cardiomyocytes. These findings indicate that
FGF21 acts on cardiomyocytes possibly in a paracrine manner
and prevents cardiac hypertrophy by activating MAPK signal-
ing through the activation of FGFR1c with β-Klotho (Table 1)
(Planavila et al., 2013).
ROLES OF FGF23 IN CARDIAC REMODELING
FGF23 is also an endocrine FGF. Fgf23 knockout mice, which
gradually died 4–13 weeks after birth, indicate that FGF23 reg-
ulates phosphate and vitamin D metabolism as a bone-derived
hormone. FGF23 also mediates its biological responses in an Fgfr-
dependent manner. However, FGF23 as well as FGF21 binds to
FGFRs with heparin/heparan sulfate with very low affinity. FGF23
was shown to efficiently bind to and activate FGFR1c with α
Klotho, which is crucial for FGF23 signaling as a cofactor (Hu
et al., 2013).
Chronic kidney disease progression results in elevated serum
levels of FGF23, which are associated with left ventricular
hypertrophy, a major contributor to cardiovascular disease
(Gutiérrez et al., 2009). As αKlotho is not expressed in the
heart and FGF23 did not activate MAPK signaling in the
heart, it has been assumed that FGF23 cannot act directly on
the heart to induce injury. However, FGF23 induced hyper-
trophic growth in cultured cardiomyocytes expressing Fgfr1c,
but not αKlotho. This result suggests αKlotho-independent
FGF23 signaling in cardiomyocytes. FGF23 injected directly
into the left ventricular myocardium in mice led to the
development of left ventricular hypertrophy. FGF23 activated
calcineurin/NFAT signaling in cultured cardiomyocytes. These
findings indicate that FGF23 promotes cardiac hypertrophy by
activating calcineurin/NFAT signaling in an endocrine man-
ner (Table 1) (Faul et al., 2011; Faul, 2012; Touchberry et al.,
2013). However, the mechanism of αKlotho-independent FGF23
signaling remains unclear. In contrast, a monoclonal FGF23
neutralizing antibody did not protect rats with chronic kid-
ney disease from cardiovascular injury, indicating that FGF23
might not have direct effects on the heart (Shalhoub et al.,
2012).
CONCLUSIONS
FGF2 promotes cardiac remodeling by activating MAPK signal-
ing through the activation of FGFR1c in a paracrine manner.
In contrast, FGF16 does not directly act on cardiac cells. FGF16
may prevent cardiac hypertrophy and fibrosis by competing with
FGF2 for the binding site of FGFR1c in a paracrine manner.
The action mechanism of FGF16 in the heart is unique. In
contrast, FGF21 is mainly a liver-derived hormone that reg-
ulates glucose and lipid metabolism in an endocrine manner.
However, Fgf21 is also expressed in cardiac cells, although this
expression is lower than that in the liver. FGF21 prevents car-
diac hypertrophy by activating MAPK signaling through the
activation of FGFR1c with β-Klotho. Although FGF21 is essen-
tially an endocrine FGF, FGF21 produced in cardiac cells may
act in a paracrine manner. Although both FGF2 and FGF21
activate MAPK signaling in cardiomyocytes, their effects are
opposite. The reason for these opposite effects remains unclear.
FGF23 is a bone-derived hormone that mainly regulates phos-
phate and vitamin D metabolism. FGF23 also induces cardiac
hypertrophy by activating calcineurin/NFAT signaling. In general,
FGF23 signaling is αKlotho/FGFR1c-dependent. However, car-
diomyocytes does not express αKlotho. It remains unclear what
precise FGFR isoform is activated by FGF23 in cardiomyocytes.
These FGFs play crucial roles in cardiac remodeling via unique
action mechanisms. However, some effects of FGF signaling on
cardiac remodeling by these FGFs appear to be contradictory.
In addition, it remains unclear which cell types really express
Fgfr1c, or how cardiomyocytes and non-cardiomyocytes talk to
each other by FGF signaling. However, these findings provide
new insights into the pathophysiological roles of FGFs in the
heart and may provide potential therapeutic strategies for heart
failure.
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